Sundia MediTech Company, Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sundia MediTech Company, Ltd. - overview
Established
2004
Location
Shanghai, -, China
Primary Industry
Pharmaceuticals
About
Sundia MediTech Company, Ltd. specializes in integrated drug discovery and development services, catering to the pharmaceutical and biotechnology sectors with innovative solutions. Founded in 2004 in Shanghai, China, Sundia MediTech Company, Ltd. focuses on drug development and has participated in 3 deals, with the latest being a Series A round of CNY 20.
000 mn led by IDG Capital. In September 2020, BioDuro-Sundia acquired a majority stake in Sundia, indicating a strategic shift to enhance their drug development capabilities. Sundia MediTech offers a comprehensive suite of drug discovery and development services tailored for pharmaceutical and biotechnology companies. Their core offerings include Drug Substance and Drug Product development, Antibody-Drug Conjugates, Peptide Compound Management, and PROTAC solutions.
These services cover the entire drug development lifecycle, particularly focusing on oncology and pharmacology applications, and cater to clients across North America, Europe, and Asia-Pacific, employing advanced technologies such as DNA-Encoded Libraries and MASH Mouse Models. Sundia MediTech generates revenue through project-based contracts and strategic partnerships within the pharmaceutical and biotechnology sectors. Their revenue model is based on long-term collaborations with milestone-based payments, including upfront fees tied to specific development milestones. The company’s flagship services are offered in holistic packages that may also involve ongoing support and consultation, allowing for tailored pricing arrangements to meet client needs.
Sundia MediTech plans to leverage recent funding to expand its product offerings and market reach. The recent acquisition by BioDuro-Sundia aims to enhance its drug development services and explore new therapeutic areas. Furthermore, the company targets market expansion initiatives in the Asia-Pacific region, specifically looking to establish a stronger foothold in key biotech hubs by the end of 2023. The CNY 20.
000 mn raised in the Series A funding round will support these growth strategies.
Current Investors
Advent International, BridgeWest, BioDuro-Sundia
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.sundia.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Sundia MediTech Company, Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Trade Sale | Completed | Sundia MediTech Company, Ltd. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.